ArticleMediators of inflammation2026
Tubal Patency Decoction and Its Ingredient β-Sitosterol Alleviate Tubal Infertility by Inhibiting Inflammation and Promoting Cilia Formation Through PGR.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tubal Patency Decoction and Its Ingredient β-Sitosterol Alleviate Tubal Infertility by Inhibiting Inflammation and Promoting Cilia Formation Through PGR.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTubal infertility is one of the major causes of female infertility. This study aimed to investigate the mechanism of action of tubal patency decoction (TPD) and its active ingredient β-sitosterol on tubal infertility.
methodsThe active ingredients of TPD and their potential targets were obtained from the TCMSP and Batman-TCM databases. The GeneCards, NCBI, and OMIM databases provided the targets associated with tubal infertility. The relationship between the components of TPD and the potential targets of tubal infertility was analyzed by String database and Cytoscape 3.8.0 software. The composition of the compounds in TPD was examined by liquid chromatography-mass spectrometry (LC-MS) assay. The effects of TPD and β-sitosterol on tubal infertility were verified by establishing a rat model of tubal infertility and a model of tubal epithelial cell inflammation.
resultsBy network pharmacological analysis, we screened 139 active ingredients of TPD, covering 523 targets, of which 34 were related to tubal infertility. β-sitosterol was identified as an important active compound. Progesterone receptor (PGR) was considered the main target of TPD and β-sitosterol in tubal infertility. Molecular docking and drug affinity responsive target stability (DARTS) assays showed that PGR binds to β-sitosterol. The results of cellular experiments confirmed that β-sitosterol and TPD-containing serum increased the cell viability of LPS-induced tubal epithelial cells, decreased the levels of inflammatory factors (IL-1β, IL-6, IL-8, and TNF-α) and myeloperoxidase (MPO), and increased the frequency of ciliary beating. The results of in vivo experiments showed that both TPD and β-sitosterol improved the conception rate and live births in tubal infertile rats and attenuated tubal inflammation and epithelial cell damage. They increased the expression of RFX2, RFX3, and FOXJ1. Silencing PGR reversed the effect of β-sitosterol on tubal epithelial cells and tubal infertile rats.
conclusionTPD and its active ingredient β-sitosterol may improve tubal infertility through PGR. These results provide a new basis for the development and application of TPD and its active ingredient β-sitosterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.